Domain Not Resolving

Google

Google Cloud

Hubspot Forms

CSO and Cambridge Site Head

Anne Phelan

Chief Technology Officer

Dan Neil

Chief Executive Officer

Joanna Shields

VP of Ops & Quality

Atima Bhatnagar

VP Drug Discovery (Chemical Sciences)

Ed Savory

VP Investor Relations

Fleur Wood

VP of AI

Nicola Richmond

Vice President (Drug Discovery)

Peter Cox

VP Pharmacology

Peter Richardson

VP of Communications

Rajin Kang

Marcello Damiani

Joerg Moeller

Michael Brennan

Co Founder & Non-Executive Director

Ivan Griffin

COO & Co-Founder

Ken Mulvany

Founder & Board Director

Chief Executive Officer and Executive Director

Brent Gutekunst

Chief Development Officer & Founder

Christina Busmalis

Chief Revenue Officer

Will Scrimshaw

General Counsel

Francois Nader

Acting Chief Executive Officer and Chair

London Public Companies With More Than $1M in Revenue

Machine Learning Companies With Fewer Than 1000 Employees (Top 10K)

United Kingdom Companies With More Than 100 Employees (Top 10K)

Europe, Middle East, and Africa (EMEA) Companies With More Than 10 Employees (Top 10K)

BenevolentAI (AMS: BAI) is a leading, clinical-stage AI-enabled drug discovery and development company listed on the Euronext Amsterdam stock exchange. Through the combined capabilities of its AI platform, scientific expertise, and wet-lab facilities, BenevolentAI is well-positioned to deliver novel drug candidates with a higher probability of clinical success than those developed using traditional methods. The Benevolent Platform™ powers a growing in-house pipeline of 13 named drug programmes and over 10 exploratory programmes, and it maintains successful collaborations with AstraZeneca, as well as leading research and charitable institutions. BenevolentAI is headquartered in London, with a research facility in Cambridge (UK) and a further office in New York.

Temasek Holdings

Private Equity Round - BenevolentAI

Woodford Investment Management

Venture Round - BenevolentAI

Computer and Software Services and Scientific Services

London

England

United Kingdom

Europe

BenevolentAI

BenevolentAI CEO is out after less than a year on the job

Losses at BenevolentAI narrow following boardroom coup

BenevolentAI: Appointment of Adviser

BenevolentAI: Leadership Team Change

BenevolentAI CFO Catherine Isted to Step Down

Astrazeneca selects SLE target under collaboration with Benevolentai

BenevolentAI and AstraZeneca collaboration yields continued success as further novel target progressed into portfolio

BenevolentAI’s Shareholder Proposal

Astrazeneca selects novel heart failure target from Benevolentai collaboration

Italy

United States

North America

Switzerland

France

HTML5

jQuery

F5 NGINX

Adobe Fonts

Google Tag Manager

Google Maps API

Google Drive

Fonts.com

HubSpot Marketing Hub

Bootstrap

BenevolentAI owns BenevolentBio

BenevolentAI S.A. operates as a clinical-stage AI-enabled drug discovery and development company. Its BenevolentAI platform powers in-house drug pipeline of drug programs. The company's therapeutic areas, include atopic dermatitis, ulcerative colitis, amyotrophic lateral sclerosis, glioblastoma multiforme, inflammatory bowel disease, antiviral, oncology, parkinson's disease, nonalcoholic steatohepatitis, fibrosis, inflammation, chronic kidney disease, and idiopathic pulmonary fibrosis. It has a collaboration with AstraZeneca to enhance understanding of complex disease biology and identify new targets. The company was founded in 2013 and is headquartered in London, United Kingdom.

BenevolentAI S.A.

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general	Mar 6, 2024 7:49 PM	10e6b479
public peers	general
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Mar 6, 2024 7:49 PM	979a3257
company summary	general
signals	general
crunchbase trigger	general	Oct 30, 2024 1:02 PM	85ffe351
crunchbase profile	general	Oct 30, 2024 1:36 PM	5426f2f4
li profile	general
translate crunchbase fundingrounds	general	Nov 6, 2024 3:12 PM	857d7f86
peers	general
news basic	general	Mar 6, 2024 7:49 PM	46b9f243
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

BAI

COM:BENEVOLENT

BenevolentAI

Last Close

0.73

22/11 16:35

Volume Today

4.65K

Avg: -